Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Pavur R Sundaresan"'
Autor:
Wolfgang Mück, Reiner Frey, Christian Scheerans, Arthur L. Mazzu, Martin Blunck, Pavur R. Sundaresan, John Lettieri
Publikováno v:
The Journal of Clinical Pharmacology. 52:1240-1247
This open-label, parallel-group, single-dose study assessed the safety and pharmacokinetics of cinaciguat, a novel soluble guanylate cyclase activator in clinical development for the treatment of acute decompensated heart failure, in individuals with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d48073c1ab68c87e3cb796de8cf90625
https://doi.org/10.1177/0091270011410567
https://doi.org/10.1177/0091270011410567
Autor:
Leonard Joseph Appleman, Arthur L. Mazzu, Pavur R. Sundaresan, Alain C. Mita, Geoffrey I. Shapiro, Frank Cihon, Anthony W. Tolcher
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To characterize the cardiovascular profile of sorafenib, a multitargeted kinase inhibitor, in patients with advanced cancer. Methods Fifty-three patients with advanced cancer received oral sorafenib 400 mg bid in continuous 28-day cycles in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fe5e149c087cec0e816a8d688913551
https://pubmed.ncbi.nlm.nih.gov/20521052
https://pubmed.ncbi.nlm.nih.gov/20521052
Autor:
E Carol Stein, Christopher Cox, Michael Weintraub, Louise Byrne, Mordechai Averbuch, Barbara Schuster, Pavur R Sundaresan
Publikováno v:
Clinical Pharmacology and Therapeutics. 51:608-614
To assess continued efficacy of anorexiants after 3 years of use, 52 participants (43% of those starting) entered a second double-blind trial to compare 60 mg sustained-release fenfluramine plus 15 mg phentermine resin versus placebo added to behavio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98224ebab3af1ef40de17e0e97a1ba3f
https://doi.org/10.1038/clpt.1992.72
https://doi.org/10.1038/clpt.1992.72
Publikováno v:
Clinical Pharmacology and Therapeutics. 51:634-641
We analyzed serum total cholesterol, triglycerides, and lipoprotein profile changes occurring in the participants (N = 121) through 210 weeks of the study. On average, baseline lipid levels were within normal limits. The most consistent changes occur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fc5398c423b69b27954b32beb79155e
https://doi.org/10.1038/clpt.1992.75
https://doi.org/10.1038/clpt.1992.75
Autor:
E Carol Stein, Manish Madan, Louise Byrne, Pavur R Sundaresan, Michael Weintraub, Gerald Ginsberg, Barbara Schuster, Andrew Balder
Publikováno v:
Clinical Pharmacology and Therapeutics. 51:595-601
Between weeks 34 and 104, we explored different schema for administering fenfluramine plus phentermine in open-label fashion. At week 34, the original placebo group participants began taking fenfluramine plus phentermine (placebo-to-active group). Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76da0f54dfc97a6341b321eb6966d616
https://doi.org/10.1038/clpt.1992.70
https://doi.org/10.1038/clpt.1992.70
Autor:
Mordechai Averbuch, Pavur R Sundaresan, E Carol Stein, Michael Weintraub, Barbara Schuster, Louise Byrne
Publikováno v:
Clinical Pharmacology and Therapeutics. 51:615-618
Participants who completed up to week 190 in the long-term weight control study were monitored after cessation of medication between weeks 190 and 210. Caloric restriction, behavior modification sessions, exercise reinforcement, and physician visits
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf537fa3a00d5dfc71ce157c6fd0af8e
https://doi.org/10.1038/clpt.1992.73
https://doi.org/10.1038/clpt.1992.73
Publikováno v:
Clinical Pharmacology and Therapeutics. 51:619-633
We analyzed the individual response patterns of all 121 participants who entered the study. Fifty-one participants completed up to week 190. In 26 completers, the response pattern consisted of an initial beneficial effect (greater than or equal to 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1907dcacf850f47ed1ee0192ce4abe2
https://doi.org/10.1038/clpt.1992.74
https://doi.org/10.1038/clpt.1992.74
Autor:
Barbara Schuster, Andrew Balder, Louis Lasagna, Michael Weintraub, Christopher Cox, Manish Madan, Pavur R Sundaresan
Publikováno v:
Clinical Pharmacology and Therapeutics. 51:586-594
To investigate the value of anorexiant medications as an adjunct to other forms of weight control therapy, we studied 121 people in a 34-week, double-blind clinical trial of 60 mg extended-release fenfluramine plus 15 mg phentermine resin versus plac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e50732a197156541f17ea604595b9f7
https://doi.org/10.1038/clpt.1992.69
https://doi.org/10.1038/clpt.1992.69
Publikováno v:
Clinical Pharmacology and Therapeutics. 51:602-607
Between weeks 104 and 156 we attempted to optimize response by adjusting the doses of fenfluramine and phentermine. Dosing changes were based on an algorithm that aimed to achieve 120% of ideal body weight (IBW) while minimizing adverse effects. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e82f0f54b276b6247b82ec68dea12cde
https://doi.org/10.1038/clpt.1992.71
https://doi.org/10.1038/clpt.1992.71
Publikováno v:
American Journal of Hypertension. 17:S16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e99a9af8006a337b1451b57b31fe99c
https://doi.org/10.1016/j.amjhyper.2004.03.034
https://doi.org/10.1016/j.amjhyper.2004.03.034